monomethyl auristatin e

Monomethyl auristatin E (MMAE) (MMAE), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin and also has inhibition of antibody-drug conjugates (ADCs) activity.

(4R,5S)-MonomethylauristatinE intermediate-6 is an intermediate reactant in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity and is widely utilized as the cytotoxic component in antibody-drug conjugates (ADC Cytotoxin).

MonomethylauristatinE intermediate-8 is an intermediate compound in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) acts as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

MonomethylauristatinE intermediate-10 is an intermediate used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) is a microtubule/tubulin inhibitor with anticancer activity. MMAE is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs) [ADC Cytotoxin].

MonomethylauristatinE intermediate-17 is an intermediate compound used in the synthesis of MonomethylauristatinE. MonomethylauristatinE (MMAE) functions as a microtubule/tubulin inhibitor with anticancer properties. It is widely utilized as the cytotoxic component in antibody-drug conjugates (ADCs).

Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.

D8-MMAE (D8-Monomethyl auristatin E) is an effective mitotic inhibitor and tubulin inhibitor, deuterated MMAE.

m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADC) for Trastuzumab, positioned distally from the monomethyl auristatin E (MMAE) payload to produce an ADC with modified hydrophilicity, antigen binding, and in vitro potency[1].

DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a potent tubulin inhibitor and toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2, serving as the cytotoxic component in this formulation.

DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, is conjugated via a DBCO-(PEG)3-vc-PAB linker.

Mal-Phe-C4-VC-PAB-MMAE is a chemical compound formed by conjugating monomethyl auristatin E (MMAE), a potent tubulin inhibitor used as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker.

Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) is a drug-linker conjugate for ADC. Mc-MMAE is a maleimidocaproyl-conjugated monomethyl auristatin E, which is a potent tubulin inhibitor.

N3-PEG3-vc-PAB-MMAE, a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), features the integration of monomethyl auristatin E (MMAE), a tubulin inhibitor, via a 3-unit polyethylene glycol (PEG) linker. This compound demonstrates significant antitumor activity.

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), consisting of the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the cleavable linker SC-VC-PAB[1].

SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker composed of the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the SuO-Val-Cit-PAB peptide.

Azido-PEG4-Val-Cit-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), incorporating the tubulin inhibitor monomethyl auristatin E (MMAE) and linked via the cleavable Azido-PEG4-Val-Cit-PAB-OH.

Fmoc-MMAE, a protective group-conjugated variant of monomethyl auristatin E (MMAE), serves as a powerful inhibitor of tubulin. It finds application in the synthesis of antibody-drug conjugates (ADC).

Dov-Val-Dil-OH is a useful chemical intermediate for synthesis of auristatin-related compounds, such as Monomethyl auristatin E (MMAE), Auristatins are antimitotic agents which inhibits cell division by blocking the polymerisation of tubulin.

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate composed of the humanized monoclonal antibody zilovertamab linked to the anti-microtubule cytotoxin monomethyl auristatin E (MMAE). Upon binding to ROR1 on tumor cells, it is rapidly internalized and directed to lysosomes for cleavage, releasing MMAE and inducing apoptosis in targeted cells. Zilovertamab vedotin has potential applications in cancer research [1].

lifastuzumAb is a humanized IgG1-like monoclonal antibody against NaPi2b, often coupled with the anti-mitotic agent monomethyl auristatin E, which inhibits cell division by blocking the polymerization of microtubule proteins.

Polatuzumab vedotin, an antibody-drug conjugate, selectively targets CD79b with a humanized anti-CD79b IgG1 monoclonal antibody bound to monomethyl auristatin E (MMAE), a robust microtubule inhibitor. This compound shows promise for research into Large B-cell lymphomas (LBCL) [1].

MC-VA-PABC-MMAE is a conjugate composed of the ADC linker peptide MC-VA-PABC and the cytotoxic agent monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization [1] [2]. It functions as an agent-linker module for antibody-drug conjugates (ADCs).

Ac-Lys-Val-Cit-PABC-MMAE is a conjugate consisting of an antibody-drug conjugate (ADC) linker (peptide Ac-Lys-Val-Cit-PABC) and the cytotoxic agent monomethyl auristatin E (MMAE), a potent tubulin polymerization inhibitor [1].

Ac-Lys-Val-Cit-PABC-MMAE (formic) is an agent-linker conjugate used in antibody-drug conjugates (ADCs), consisting of a peptide linker (Ac-Lys-Val-Cit-PABC) attached to the cytotoxic agent Monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization[1].